Articles From: Obama says Sony 'made a mistake' cancelling film to Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade®


2014/12/19
By Devlin Barrett and Byron Tau President Barack Obama criticized Sony Pictures Friday for pulling a movie out of theaters in response to a hack attack U.S. officials blame on North Korea, saying it sets a bad precedent and could encourage further censorship.
Sign-up for Obama says Sony 'made a mistake' cancelling film investment picks
2015/2/10
By Devlin Barrett And Christopher M.
Sign-up for U.S. Seeks Guilty Pleas From 4 Banks in Currency Antitrust Probe investment picks
2015/2/12
By Devlin Barrett The head of the House Judiciary Committee warned the Obama administration at a hearing Thursday of a coming political battle if the Justice Department doesn't hand over documents related to its multibillion-dollar settlements with big banks.
Sign-up for Lawmaker Warns Obama Administration of Battle Over Bank-Settlement Documents investment picks
2015/2/10
By Devlin Barrett WASHINGTON--A federal judge tossed out part of a privacy group's lawsuit against the National Security Agency Tuesday, saying to let it proceed would damage national security.
Sign-up for Judge Denies Portion of Privacy Group's Lawsuit Against NSA investment picks
2015/2/10
By Devlin Barrett WASHINGTON--A privacy watchdog group has filed a lawsuit seeking details of a Justice Department surveillance program that uses secret airborne technology to scan large numbers of Americans' cellphones while hunting criminal suspects.
Sign-up for Privacy Group Sues Over U.S. Cellphone Surveillance Program investment picks
2015/2/22
By Dhanya Ann Thoppil BANGALORE, India--As its growth slows, India's technology services outsourcing industry is struggling to become less dependent on peddling the services of inexpensive programmers and trying to enter new businesses like off-the-shelf software and helping customers with big data and cloud computing.
Sign-up for Indian Outsourcers Struggle to Evolve as Growth Slows investment picks
2015/2/16
By Dhanya Ann Thoppil BANGALORE-- Infosys Ltd.
Sign-up for Infosys to Buy Automation Technology Company Panaya investment picks
2015/1/21
By Diana Furchtgott-Roth, MarketWatch The president seems to be more interested in inducing class warfare You have to hand it to President Obama.
Sign-up for UPDATE: Obama is decidedly unserious with his tax-increase plans investment picks
2015/1/21
By Diana Furchtgott-Roth, MarketWatch Americans are interested in tax cuts, not hikes You have to hand it to President Obama.
Sign-up for UPDATE: Obama's joke of a tax plan only fuels class warfare investment picks
2014/12/23
By Diana Furchtgott-Roth, MarketWatch Even though I picked large, solid companies, they couldn't outperform broad indexes At this time last year I wrote in a column: "With the stock market achieving record highs at the end of 2013, some might think it is time to take their winnings and go into cash.
Sign-up for UPDATE: What I learned with my 10 stock recommendations a year ago investment picks
2015/1/30
By Diana Furchtgott-Roth, MarketWatch The National Labor Relations Board wants workers to be able to unionize McDonald's Corp.'s new CEO, Steve Easterbrook, has a major task in front of him in addition to increasing sales of burgers: getting his company out of the clutches of the National Labor Relations Board.
Sign-up for UPDATE: McDonald's, already struggling, now has to fight the government investment picks
2015/2/12
By Diana Furchtgott-Roth, MarketWatch His remarks on health care come as the office-supply chain is under antitrust review The Staples office-supply chain is now the latest victim in a series of politically charged attacks from the White House on corporations.
Sign-up for UPDATE: With Staples, Obama once again interferes with the private sector investment picks
2015/2/12
By Diana Furchtgott-Roth, MarketWatch His remarks on health care come as the office-supply chain is under antitrust review The Staples office-supply chain is now the latest victim in a series of politically charged attacks from the White House on corporations.
Sign-up for With Staples, Obama once again interferes with the private sector investment picks
2015/1/22
By Dinny McMahon BEIJING -- The Chinese government is proposing to regulate a murky corporate structure that has allowed China's Internet giants to court foreign shareholders.
Sign-up for UPDATE: China looks to ease foreign-investment rules covering Internet companies investment picks
2014/12/8
- 2015 Estimated 7 - 11% Underlying Sales Growth and Adjusted EPS of $3.90 - $4.10 - Pipeline of Innovative Technologies Positions Company for Sustainable Growth NEW YORK , Dec.
Sign-up for Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference investment picks
2015/1/22
First Quarter Results Include: - Record Net Sales of $303.6 Million, Up 18.8 Percent Over Prior Year - GAAP Operating Income of $29.7 Million, Up 315.3 Percent Over Prior Year - Record Non-GAAP Operating Income of $74.2 Million, Up 37.0 Percent Over Prior Year - Record Operating Cash Flow of $66.9 Million - Record Free Cash Flow of $53.8 Million ALISO VIEJO, Calif.
Sign-up for Microsemi Reports First Quarter 2015 Results investment picks
2015/2/5
Solid profitability driven by net sales of $210 million and 14.5% gross margin IRVINE, Calif.
Sign-up for MFLEX Reports Strong 2014 Calendar Fourth Quarter Financial Results investment picks
2015/2/22
PROVIDING FIRST QUARTER 2015 CASH EPS GUIDANCE DENDREON ACQUISITION EXPECTED TO CLOSE FEBRUARY 23, 2015 VALEANT TO ACQUIRE SALIX PHARMACEUTICALS FOR $158.00 PER SHARE IN CASH FULL YEAR 2015 GUIDANCE, REFLECTING SALIX AND DENDREON, AS WELL AS EXPECTED BUSINESS OUTPERFORMANCE, WILL BE UPDATED ON FIRST QUARTER 2015 EARNINGS CALL VALEANT TO HOLD CONFERENCE CALL TO DISCUSS SALIX TRANSACTION AND FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS AT 8:00 AM ET ON MONDAY, FEBRUARY 23 LAVAL, Quebec , Feb.
Sign-up for Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results investment picks
2015/2/22
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results PROVIDING FIRST QUARTER 2015 CASH EPS GUIDANCE DENDREON ACQUISITION EXPECTED TO CLOSE FEBRUARY 23, 2015 VALEANT TO ACQUIRE SALIX PHARMACEUTICALS FOR $158.00 PER SHARE IN CASH FULL YEAR 2015 GUIDANCE, REFLECTING SALIX AND DENDREON, AS WELL AS EXPECTED BUSINESS OUTPERFORMANCE, WILL BE UPDATED ON FIRST QUARTER 2015 EARNINGS CALL VALEANT TO HOLD CONFERENCE CALL TO DISCUSS SALIX TRANSACTION AND FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS AT 8:00 AM ET ON MONDAY, FEBRUARY 23 Canada NewsWire LAVAL, Quebec , Feb.
Sign-up for Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results investment picks
2015/2/10
Please replace the release dated Feb.
Sign-up for CORRECTING and REPLACING Tortoise Capital Advisors Announces Distribution Amounts and Dates for Closed-End Funds (TYG, NTG, TTP, NDP, TPZ) investment picks
2014/12/22
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta), seeking an additional indication in pediatric patients six years old and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Sign-up for Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta® investment picks
2014/12/19
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Pfizer has received EU marketing authorization for DUAVIVE® (conjugated estrogens/bazedoxifene (BZA/CE)) from the European Commission.
Sign-up for Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus investment picks
2015/1/8
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Melinta Therapeutics reported positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to evaluate delafloxacin, an investigational fluoroquinolone, compared with vancomycin + aztreonam for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin met the study’s primary objective endpoint of a reduction in the measurement of lesion erythema at the primary infection site at 48- to- 72 hours, the endpoint required by the U.S. Food and Drug Administration (FDA). Delafloxacin also was comparable to vancomycin in the study’s secondary endpoints, including investigator assessment of signs and symptoms of infection at the follow-up visit, a metric required by the European Medicines Agency (EMA).
Sign-up for Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV investment picks
2014/12/26
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Spectrum Pharmaceuticals (NASDAQ: SPPI) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Captisol-enabled™ Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Sign-up for Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan investment picks
2015/1/9
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Retrophin, Inc. (NASDAQ:RTRX) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). “Sparsentan has the potential to be a significant medicine, and could transform the treatment of FSGS,” said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals.
Sign-up for Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan investment picks
2015/2/2
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Matthew W.
Sign-up for Ligand Promotes Matthew W. Foehr to President investment picks
2015/2/3
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the United States and additional territories.
Sign-up for Ligand Signs License Agreement with Sermonix for Lasofoxifene investment picks
2015/1/28
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that company executives will be presenting at the following conferences: A live webcast of the presentations will be available on the Company’s website www.ligand.com .
Sign-up for Ligand to Present at BIO CEO and RBC Capital Markets Global Healthcare Conferences in February investment picks
2015/1/27
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter of 2014 financial results on February 9, 2015.
Sign-up for Ligand to Report Fourth Quarter Results on February 9th investment picks
2015/2/6
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for eltrombopag (Revolade ® ), seeking an additional indication for the treatment of pediatric patients (age 1 year and above) with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids or immunoglobulins.
Sign-up for Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade® investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Obama says Sony 'made a mistake' cancelling film to Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade®
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent